Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.820
+0.040 (2.25%)
Aug 7, 2026, 3:04 PM EDT - Market open
Gain Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Gain Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $7.20. The average 1-year stock price forecast is 295.60% higher than the current stock price, while the lowest is $5.00 (+174.73%) and the highest is $8.00 (+339.56%).
Price Target: $7.20 (+295.60%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jul 2, 2026.
Analyst Ratings
The average analyst rating for Gain Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $7 | Buy | Maintains | $7 | +284.62% | Jul 2, 2026 |
| Roth MKM | Roth MKM | Buy Maintains $8 | Buy | Maintains | $8 | +339.56% | Jul 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +339.56% | Jul 1, 2026 |
| BTIG | BTIG | Buy Maintains $5 | Buy | Maintains | $5 | +174.73% | May 26, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +339.56% | May 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.60
from -0.61
EPS Next Year
-0.60
from -0.60
EPS and Forward PE are based on non-GAAP adjusted numbers.